RGLS Quote, Financials, Valuation and Earnings

BioCardia has a net margin of -- compared to Regulus Therapeutics's net margin of -54866.67%. Regulus Therapeutics's return on equity of -- beat BioCardia's return on equity of -938.6%.

Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 6.02%. On the other hand BioCardia has an analysts' consensus of $6.00 which suggests that it could grow by 162.01%. Given that BioCardia has higher upside potential than Regulus Therapeutics, analysts believe BioCardia is more attractive than Regulus Therapeutics.

Regulus Therapeutics has a beta of 0.354, which suggesting that the stock is 64.643% less volatile than S&P 500. In comparison BioCardia has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.526%.

Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioCardia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. BioCardia pays out -- of its earnings as a dividend.

Regulus Therapeutics quarterly revenues are --, which are smaller than BioCardia quarterly revenues of $3K. Regulus Therapeutics's net income of -$9.6M is lower than BioCardia's net income of -$2.7M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while BioCardia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 18.65x for BioCardia. Usually stocks with elevated PS ratios are considered overvalued.

Cormedix has a net margin of -- compared to Regulus Therapeutics's net margin of 52.82%. Regulus Therapeutics's return on equity of -- beat Cormedix's return on equity of 23.7%.

Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 6.02%. On the other hand Cormedix has an analysts' consensus of $16.83 which suggests that it could grow by 17.31%. Given that Cormedix has higher upside potential than Regulus Therapeutics, analysts believe Cormedix is more attractive than Regulus Therapeutics.

Regulus Therapeutics has a beta of 0.354, which suggesting that the stock is 64.643% less volatile than S&P 500. In comparison Cormedix has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.377%.

Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Regulus Therapeutics quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Regulus Therapeutics's net income of -$9.6M is lower than Cormedix's net income of $20.6M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Cormedix's PE ratio is 65.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 10.73x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Regulus Therapeutics's net margin of 21.63%. Regulus Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 6.02%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.98%. Given that Pfizer has higher upside potential than Regulus Therapeutics, analysts believe Pfizer is more attractive than Regulus Therapeutics.

Regulus Therapeutics has a beta of 0.354, which suggesting that the stock is 64.643% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.09% to investors and pays a quarterly dividend of $0.43 per share. Regulus Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regulus Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Regulus Therapeutics's net income of -$9.6M is lower than Pfizer's net income of $3B. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -- compared to Regulus Therapeutics's net margin of -169.47%. Regulus Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -49.69%.

Regulus Therapeutics has a consensus price target of $8.80, signalling upside risk potential of 6.02%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $47.00 which suggests that it could grow by 0.54%. Given that Regulus Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Regulus Therapeutics is more attractive than SpringWorks Therapeutics.

Regulus Therapeutics has a beta of 0.354, which suggesting that the stock is 64.643% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.699, suggesting its less volatile than the S&P 500 by 30.122%.

Regulus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regulus Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Regulus Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.1M. Regulus Therapeutics's net income of -$9.6M is higher than SpringWorks Therapeutics's net income of -$83.2M. Notably, Regulus Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regulus Therapeutics is -- versus 15.84x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.